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Cerebral non-oxidative carbohydrate consumption may be driven by a β2-adrenergic
mechanism. This study tested whether the 46G > A (G16R) single nucleotide
polymorphism of the β2-adrenergic receptor gene (ADRB2) influences the metabolic
and cerebrovascular responses to administration of adrenaline. Forty healthy Caucasian
men were included from a group of genotyped individuals. Cardio- and cerebrovascular
variables at baseline and during a 60-min adrenaline infusion (0.06 µg kg−1 min−1)
were measured by Model flow, near-infrared spectroscopy and transcranial Doppler
sonography. Blood samples were obtained from an artery and a retrograde catheter
in the right internal jugular vein. The ADRB2 G16R variation had no effect on baseline
arterial glucose, but during adrenaline infusion plasma glucose was up to 1.2 mM
(CI95: 0.36 – 2.1, P < 0.026) higher in the Gly
16 homozygotes compared with Arg16
homozygotes. The extrapolated steady-state levels of plasma glucose was 1.9mM
(CI95: 1.0 –2.9, PNLME < 0.0026) higher in the Gly
16 homozygotes compared with
Arg16 homozygotes. There was no change in the cerebral oxygen glucose index
and the oxygen carbohydrate index during adrenaline infusion and the two indexes
were not affected by G16R polymorphism. No difference between genotype groups
was found in cardiac output at baseline or during adrenaline infusion. The metabolic
response of glucose during adrenergic stimulation with adrenaline is associated to
the G16R polymorphism of ADRB2, although without effect on cerebral metabolism.
The differences in adrenaline-induced blood glucose increase between genotypes
suggest an elevated β2-adrenergic response in the Gly
16 homozygotes with increased
adrenaline-induced glycolysis compared to Arg16 homozygotes.
Keywords: β2-adrenergic receptor gene, adrenergic β2-receptors, G16R, cardiac output, blood glucose,
oxygenation glucose index
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INTRODUCTION
Cerebral energy metabolism at rest is provided almost exclusively
by glucose and the molar ratio between the cerebral uptake of
O2 to that of glucose (the O2-glucose index; OGI) is close to
6 (Quistorff et al., 2008). Adrenergic mechanisms influence
cerebral energy metabolism (Bryan, 1990). Adrenaline increases
the cerebral non-oxidative carbohydrate consumption (Seifert
et al., 2009), presumably by a β2 adrenergic mechanism
because propranolol, a combined β1- and β2-adrenergic
receptor antagonist, attenuates cerebral carbohydrate uptake
(Schmalbruch et al., 2002; Larsen et al., 2008), whereas
metoprolol, a selective β1 adrenergic receptor antagonist, is
without that effect (Dalsgaard et al., 2004). During maximal
whole body exercise, the cerebral oxygen carbohydrate index
(OCI; cerebral uptake of O2/(glucose + 1/2 lactate) decreases
from a resting value of ∼5.7 to reach a low value of 1.7
(Volianitis et al., 2008) that is associated with high levels of
plasma catecholamine (Holmqvist et al., 1986; Nielsen, 2003).
The β2-adrenergic receptor is encoded by an intronless gene
(ADRB2) located on chromosome 5 (5q31-32) that contains
several single nucleotide polymorphisms (Leineweber et al.,
2004). The non-synonymous 46 G > A (G16R) single nucleotide
polymorphism leading to an amino acid substitution of Gly16Arg
segregates with hypertension and asthma (Zaugg and Schaub,
2005; Sayers, 2013) and homozygote Gly16 subjects demonstrate
a larger cardiac output (CO) both at rest and during exercise
compared with homozygote Arg16 subjects (Snyder et al., 2006a;
Rokamp et al., 2013). Differences in phenotype may arise from
a higher receptor density in homozygote Gly16 subjects (Snyder
et al., 2006b). However, differences in phenotype may also be a
result of differences in sensitivity to β-agonists, as the Arg16 allele
is associated with enhanced agonist-mediated desensitization
(Dishy et al., 2001) and attenuated blood flow during infusion of a
β-agonist in the brachial artery (Garovic et al., 2002). In contrast,
Arg16 homozygotes had increased β2-receptor sensitivity after
hypoglycemia whereas no effect was seen in Gly16 homozygotes
(Schouwenberg et al., 2011). Also, the G16R polymorphism has
been associated with insulin resistance (Masuo et al., 2005)
and obesity (Daghestani et al., 2012), albeit with inconsistent
results (Gjesing et al., 2009). Another polymorphisms in the β2-
adrenergic receptor gene of functional importance is the 79C
> G Q27E and in contrast to the Arg16 allele, the Glu27 allele
is associated with increased agonist-mediated responsiveness in
vasculature (Dishy et al., 2001). The role of haplotypes within
ADRB2 is, however, not known, but Rokamp et al. (2013) found
no impact of haplotypes on cardiac output.
The adrenaline driven increase in cerebral non-
oxidative carbohydrate consumption (Seifert et al., 2009),
if mediated by a β2 adrenergic mechanism, could be
Abbreviations: ADRB2, β2-adrenergic receptor gene; ANOVA, analysis of
variance; CBF, cerebral blood flow; CO, cardiac output; HR, heart rate; LME,
linear mixed effects models; MAP, mean arterial pressure; MCAvmean, velocity
in the middle cerebral artery; NLME, non-linear mixed effects model; OCI, the
cerebral oxygen carbohydrate index; OGI, the cerebral O2-glucose index; SV, stroke
volume; SVR, systemic vascular resistance; ScO2, frontal lobe oxygenation; SmO2,
muscle oxygenation.
influenced by genetic polymorphism in the β2-adrenergic
receptor. We speculated that the difference in phenotype
between Gly16 homozygotes and Arg16 homozygotes could
mimic that Arg16 homozygotes was influenced by a β2
adrenergic receptor antagonist, leading to decreased cerebral
carbohydrate uptake under adrenergic stress compared to Gly16
homozygotes.
No study describes the influence of genetic polymorphism
in the β2-adrenergic system on brain metabolism. We aimed
to investigate cardiovascular and cerebral metabolic effects of
adrenergic stimulation in humans in relation to the G16R
genotype. We hypothesized that cardiac output (CO) at rest
and during adrenergic stimulation would be increased in Gly16
homozygotes and that the expected reduction in cerebral
metabolic ratio during adrenergic stimulation would be more
pronounced in Gly16 homozygotes, reflecting increased β2-
adrenergic response compared to Arg16 homozygotes.
METHODS
Forty healthy non-smoking Caucasian male subjects (age: 26 ±
5 years; height: 184 ± 6 cm; body weight: 77 ± 8 kg; body mass
index: 23± 2 kg/m2) were included in the study following verbal
and written informed consent as approved by the Comittees on
Biomedical Research Ethics of the Capital Region of Denmark,
The Regional Committee A (H-4-2010-027) and the Danish
Data Protection Agency (2011-41-6600). To obtain groups with
similar age, height, and weight the subjects were recruited from
a cohort of genotyped healthy subjects (Rokamp et al., 2013). All
participants completed the entire study protocol. The genotype
groups included 12 G16R heterozygotes, 12 Arg16 homozygotes,
and 16 Gly16 homozygotes. Age, height, weight, and body mass
index were similar in the three groups (Table 1).
The subjects were studied after an overnight fast and
strenuous exercise was not allowed 24 h prior to the study. Under
local anesthesia (2% lidocaine), a catheter (Edwards Lifesciences,
Irvine, CA) was inserted in the right internal jugular vein and
advanced to its bulb using Seldinger technique. The position of
the catheter was verified by a “water-fall-like” sound following
infusion of saline and eventually by nociception related to the
mastoid process and when so, the catheter was withdrawn
about two millimeters. An arterial catheter (1.1mm, 20 gauge)
was inserted in the brachial artery of the non-dominant arm.
For drug administration, a catheter (Cavafix MT134, Braun,
Melsungen, Germany) was advanced to the subclavian vein
through a cubital vein. Catheters were connected to a transducer
(Edwards Life Sciences, Irvine, CA) positioned at heart level
(5 cm below sternum) and attached to a monitor (Dialogue-2000
IBC-Danica Electronic, Denmark) for determination of mean
arterial pressure (MAP) and heart rate (HR). Stroke volume
(SV), CO and systemic vascular resistance (SVR) were derived by
pulse contour analysis technology (BeatScope; Finapress Medical
System BV, Amsterdam, Netherlands) adjusting for weight,
height, age, and gender. Data were analog-digital converted and
sampled at 100Hz (Powerlab, ADInstruments, Colorado Springs,
CO, USA).
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TABLE 1 | Cardiovascular variables during rest (baseline) according to the
Gly16Arg polymorphism of the β2-adrenergic receptor gene (n = 40).
Baseline
GlyGly GlyArg ArgArg PANOVA
N 16 12 12 -
Age (years) 25 ± 4 26 ± 6 26 ± 5 >1.0
Height (cm) 186 ± 6 183 ± 5 182 ± 7 >1.0
Weight (kg) 78 ± 8 78 ± 7 76 ± 9 >1.0
Body mass index (kg/m2) 23 ± 2 23 ± 2 23 ± 2 >1.0
SYS (mmHg) 130 ± 14 125 ± 9 125 ± 13 >1.0
DIA (mmHg) 67 ± 9 68 ± 5 65 ± 6 >1.0
MAP (mmHg) 87 ± 10 87 ± 8 85 ± 8 >1.0
HR(beat min−1 ) 63 ± 13 61 ± 10 57 ± 8 >1.0
SV (ml) 110 ± 7 106 ± 11 112 ± 5 >1.0
SVI (ml m−2 ) 55 ± 3 54 ± 4 58 ± 4 >1.0
CO (L min−1) 6.8 ± 1.2 6.4 ± 0.8 6.3 ± 1.0 >1.0
CI ((L min−1 ) m−2) 3.4 ± 0.8 3.2 ± 0.4 3.2 ± 0.5 >1.0
SVR (dyn s cm−5) 1,122 ± 277 1,112 ± 201 1,108 ± 224 >1.0
MCA Vmean 62 ± 10 60 ± 10 57 ± 11 >1.0
PI 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.2 >1.0
ScO2 (%) 78 ± 8 77 ± 7 77 ± 4 >1.0
SmO2 (%) 82 ± 8 80 ± 10 81 ± 7 >1.0
Values are mean± SD. SYS, Systolic blood pressure; DIA, diastolic blood pressure; MAP,
middle arterial pressure; HR, heart rate; SV, stroke volume; SVI, stroke volume index; CO,
cardiac output; CI, cardiac index; SVR, systemic vascular resistance; MCA Vmean, mean
flow velocity (a. cerebri media); PI, pulsatile index (a. cerebri media); ScO2, cerebral frontal
lobe oxygenation; SmO2, muscle oxygenation. PANOVA values are corrected for multiple
testing by the bonferroni method, therefore values above 1.0 appear.
Near infrared spectroscopy (INVOS-5100c, Covidien,
Mansfield, MA, USA) was used to assess frontal lobe (ScO2)
and muscle oxygenation (SmO2). The INVOS-5100c uses an
emitter-detector distance of 3 and 4 cm and infrared light at
730 and 808 nm to avoid influence from cutaneous blood flow.
One optode were applied above the supraorbital edge to assess
ScO2 and a second optode was placed on the middle part of the
thigh for assessment of SmO2. Transcranial Doppler sonography
(2MHz probe, Multi-Dop, DWL, Singen, Germany) determined
velocity in the middle cerebral artery (MCAvmean) from the
temporal ultrasound window. The best signal-to-noise ratio was
obtained at a depth of 44–56mmwith the Doppler probe secured
by a headband or while handheld.
Protocol
Following catheterization the subjects’ rested supine for 30min.
Adrenaline was prepared in 100ml isotone saline solution
according to weight and infused for 60min at 0.06 µg
kg−1 min−1. After termination of the infusion, the subjects
were observed for another 30min. Simultaneous arterial
and venous blood samples were obtained in pre-heparinized
syringes (QS50, Radiometer, Copenhagen, Denmark) and
immediately purged of any atmospheric content followed by
analysis using an ABL 725 (Radiometer). Blood sampling
and cardiovascular variables were obtained at rest and at
2.5min intervals during the initial 10min of the infusion
and thereafter at 10 min intervals until the infusion was
terminated.
Purification of DNA and Genotyping
DNA was purified from 200 µl frozen blood samples by
the magnetic bead based MagneSil R© Blood Genomic, Max
Yeld System (Promega, Madison WI, USA). Genotyping was
performed using TaqMan assay with the following rs and AB
number: rs1042713, c___2084764_20. The assay was analyzed
using real-time polymerase chain reaction by an Applied
Biosystem 7,500 Fast Real Time polymerase chain reaction device
according to the manufacturer’s instruction (Applied Biosystem,
Lincoln, CA, USA).
Calculations
The OCI and the ratio taking only glucose into account (OGI,
O2/glucose; Fox et al., 1988) were calculated and both ratios were
considered independent of changes in cerebral blood flow (CBF)
(Dalsgaard, 2006). Although pyruvate is a viable carbohydrate
source in fueling cerebral activity, pyruvate was omitted in the
analysis based on the assumption that its uptake by the brain
is at least an order of magnitude smaller than that of lactate
(Rasmussen et al., 1985).
The cumulated cerebral uptake of glucose, lactate and O2
was calculated from the arterial and internal jugular venous
concentrations assuming a resting CBF of 700ml min−1
(Jørgensen et al., 1992), adjusted according to changes in
MCAvmean (Quistorff et al., 2008): 6t(0)/t(n) substrate uptake =
{(t1 - t0)× [arterial– venous difference substrate1]× CBF1 + (t2
− t1) × [arterial– venous difference substrate2] ×CBF2 + (tn −
tn−1)× [arterial– venous difference substraten]×CBFn}.
Statistics
Statistically analysis was performed using R version 3.0.3
with add-on packages: “nlme” (Pinheiro, Bates, DebRoy,
Sarkar, and R Core Team, version 3.1-113), “ggplot2,” “grid,”
and “reshape 2” attached. The alpha-level was set to 5%.
Baseline data were analyzed with standard parametric models
[Analysis of variance (ANOVA) and/or t-test] or non-parametric
tests (Kruskal-Wallis) if residual analysis revealed non-normal
distributions. For repeated measurements of CO, arterial-
glucose and arterial-lactate, a non-linear mixed effects model
(NLME) was used to take into account within subject correlated
data. The proposed dose-response relationship is based on
a standard first-order pharmacokinetic model following the
formula:
f (t) = β · (1− e−γ · t)+ α
Each individual was allowed (i.e., random effect of) his own
values of intercept (α), steady-state (β) and rate of increase (γ)
parameters. Briefly, α models the individual’s baseline value,
β is the estimated value approached asymptotically as time
increases (in practice around 60 min), and γ determines the
steepness of the initial slope. A genotype effect on each of the
parameters α, β, and γ was tested with the “nlme” package.
Linear mixed effects models (LME) were constructed in cases
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where the kinetic model (Equation 1) could not be fitted using
the non-linear mixed effects function in R. In each group
the change from baseline was analyzed based on the mixed
model with the main effects of group, time, and interaction.
Models were fit using maximum-likelihood. Assumptions of
normality of error-distribution were assessed with residual plots.
In addition, models were validated by influence analysis to
verify that no single measurement or individual could change
conclusions. Mean values with SD are reported unless otherwise
indicated. The bonferroni method was used to correct for
multiple comparisons. Thus P-values was multiplied with the
number of tested variables (n = 26) and therefor P > 1.0 can
appear in the text, P-values lower than 0.05 were regarded as
statistically significant.
RESULTS
Cardiovascular Variables
Cardiovascular variables are presented in Figure 1.
Cardiovascular variables showed no significant differences
between genotypes at baseline (Table 1) or during adrenaline
infusion (Figure 1).
Metabolic Variables
Distributions of metabolic variables are presented in Figures 2,3.
Baseline arterial glucose was 5.6 ± 0.4mM with no significant
differences between genotypes (PANOVA > 1.0). During
adrenaline infusion (after 60min of infusion) plasma glucose
was up to 1.2mM (CI95: 0.36-2.1, P < 0.026) higher in the Gly
16
homozygotes compared with Arg16 homozygotes. Fitting the
non-linear mixed effects model (Equation 1), there was an effect
of the G16R polymorphism on the extrapolated steady-state level
(β) (PNLME < 0.0026), but not on the intercept (α), or rate of
increase (γ). At the extrapolated steady-state level (not shown
on the figure) the Gly16 homozygotes had an arterial glucose
that was 1.9mM (CI95: 1.0–2.9, PNLME < 0.0026) higher than in
the Arg16 homozygotes. There was no significant difference in
arterial glucose during adrenaline infusion between the G16R
heterozygotesand Arg16 homozygotes (PNLME = 0.16).
Baseline arterial lactate was 0.7± 0.3 mM without differences
between genotypes after correction for multiple testing (PANOVA
FIGURE 1 | Cardiovascular variables according to the β2-adrenergic receptor gene G16R polymorphism at baseline and during adrenaline infusion (n = 40). The
mean and SD of each genotype group is presented to each time point. Baseline measurements are followed by adrenaline infusion that is initiated at time 0. Cardiac
output (CO), heart rate (HR), stroke volume (SV), middle arterial pressure (MAP), systemic vascular resistance (SVR), cerebral frontal lobe oxygenation (ScO2), muscle
oxygenation (SmO2), and mean middle cerebral artery velocity (MCAvmean). There were no significant differences between genotypes in any of the cardiovascular
variables. Adrenaline increased CO (P < 0.0026) (A), SV (P < 0.0026) (B), HR (P < 0.0026) (C), ScO2 (P < 0.0026) (G), SmO2 (P < 0.0026) (H) compared to
baseline, but decreased MAP (P < 0.0026) (D) and SVR (P < 0.0026) (E), while MCAvmean did not change significantly from baseline (P > 1.0) (F). Following
termination of the adrenaline infusion cardiovascular variables approached the baseline levels.
Frontiers in Physiology | www.frontiersin.org 4 September 2017 | Volume 8 | Article 661
Rokamp et al. ADRB2 G16R Polymorphism and Response to Adrenaline
FIGURE 2 | Cardiac output (CO), arterial glucose and arterial lactate according to the β2-adrenergic receptor gene G16R polymorphism at baseline and during
adrenaline infusion (n = 40). Baseline measurements are followed by adrenaline infusion that is initiated at time 0. The figure shows the non-linear mixed effects model
(Equation 1), with an underlay were the mean and SD of each genotype group is presented to each time point. There were no significant differences between
genotypes in CO (PANOVA > 1.0) (A). Arterial glucose (B) was 1.2 mM (CI95: 0.36−2.1, P < 0.026) higher in the Gly
16 homozygotes compared with Arg16
homozygotes after 60 min of adrenaline infusion. At the extrapolated steady-state level (not shown on the figure) the Gly16 homozygotes had an arterial glucose that
was 1.9 mM (CI95: 1.0–2.9, PNLME < 0.0026) higher than in the Arg
16 homozygotes. There were no significant differences between genotypes in arterial lactate
(PANOVA = 0.78) (C).
= 0.78). The non-linear mixed effects model showed no
significant effect of the G16R polymorphism on the baseline
(intercept) parameter α (PNLME >1.0), the steady state parameter
β (PNLME > 1.0), or on the rate of increase γ (PNLME > 1.0)
(Figure 2C).
In methemoglobin a genotype specific difference was
found both at baseline and during adrenaline infusion (P
= 0.0234) (Figure 3G). Adrenaline infusion however, did not
change the levels of methemoglobin, as compared to baseline
(P < 0.098).
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FIGURE 3 | Arterial blood gas variables according to the β2-adrenergic receptor gene G16R polymorphism at baseline and during adrenaline infusion (n = 40). The
mean and SD of each genotype group is presented to each time point. Baseline measurements are followed by adrenaline infusion that is initiated at time 0. Arterial
pH (pH), arterial CO2 tension (pCO2), arterial O2 tension (pO2), arterial hemoglobin (Hb), arterial oxygen saturation (O2 sat.), arterial fraction of carboxyhemoglobin
(COHb), arterial methemoglobin (metHb), arterial standard base excess (std. BE), and arterial standard hydrogen carbonate (HCO3−). Following baseline arterial blood
gas variables for did not differ between genotypes, pH (PANOVA > 1.0) (A), pCO2 (PANOVA > 1.0) (B), pO2 (PANOVA > 1.0) (C), Hb (PANOVA > 1.0) (D), O2 sat
(PANOVA < 0.68) (E), Hb (PANOVA > 1.0) (F), hematocrite (PANOVA >1.0) (H), Glucose (PANOVA >1.0) (I), lactate (PANOVA = 0.78) (J), std. BE (PANOVA > 1.0) (K),
std HCO3− (PANOVA > 1.0) (L). Except for glucose none of these variables was associated with a genotype specific difference during adrenaline infusion. In metHb a
genotype specific difference was found both at baseline and during adrenaline infusion (P = 0.0234) (G). Adrenaline infusion however, did not change the levels of
methemoglobin, as compared to baseline (P < 0.098).
All other baseline arterial blood gas variables did not differ
between genotypes and in none of these variables a genotype
specific difference during adrenaline infusion was found. All
metabolic variables changed during adrenaline infusion as shown
in Figure 3.
Whole Brain Metabolism
The non-linear model (Equation 1) did not fit the brain
metabolic indices. Results from linear mixed effects models
including duration of adrenaline infusion as predictor of the
investigated brain metabolic indices are reported in Figure 4.
With the homozygote Gly16 polymorphism as a predictor of
both slope (interaction) and intercept (additive effect), there was
no significant effect of genotype in any of the brain metabolic
indices.
DISCUSSION
In contrast to our hypothesis, the cerebral uptake of glucose was
not different among the genotype groups. Seifert et al. (2009)
suggest that adrenaline is responsible for the increase in non-
oxidative cerebral carbohydrate consumption. Comparing this
study with the work by Seifert et al. (2009), the adrenaline
infusion rate was lower (0.06 vs. 0.08 µg kg−1 min−1),
and our subjects increased their heart rate to below 80 bpm
compared to 90 bpm, suggesting a difference in adrenergic
stimulation. Apart from the study of Seifert et al. (2009),
the hypothesis that adrenaline should stimulate the cerebral
uptake of glucose and lactate, generates from studies on
the effects of exercise in rats (Schmalbruch et al., 2002)
and humans (Dalsgaard et al., 2004; Larsen et al., 2008;
Volianitis et al., 2008) were it is likely that the adrenergic
stimulation was increased compared to that in the present
study.
Snyder et al. (2006a) and Rokamp et al. (2013) found
baseline CO increased in Gly16 homozygotes compared with
Arg16 homozygotes. We found the same effect size (∼0.5 L
min−1) although the difference was not statistically significant.
This study differs from the previous studies by the population
consisting of young males compared to mixed groups (Snyder
Frontiers in Physiology | www.frontiersin.org 6 September 2017 | Volume 8 | Article 661
Rokamp et al. ADRB2 G16R Polymorphism and Response to Adrenaline
FIGURE 4 | Cerebrovascular variables according to the β2-adrenergic receptor gene G16R polymorphism at baseline and during adrenaline infusion (n = 40).
Baseline measurements are followed by adrenaline infusion that is initiated at time 0. Oxygen-glucose index (OGI), oxygen-carbohydrate index (OCI), arterial—venous
difference in oxygen saturation (A-V diff SO2), arterial—venous difference in lactate (A-V diff lactate), arterial—venous difference in glucose (A-V diff glucose),
arterial—venous difference in glucose + ½ lactate (A-V diff glucose + ½ lactate). There were no significant changes in the brain metabolic indices at baseline or at
adrenaline infusion, oxygen-glucose index (PLME = 0.26) (A) oxygen carbohydrate index (PLME > 1.0) (B), A-V diff SO2 (PLME = 0.52) (C), A-V diff lactate (PLME =
0.16) (D), A-V diff glucose (PLME = 0.78) (E) and A-V diff glucose + ½ lactate (PLME > 1.0). There were no significant differences between the genotype groups in any
of the brain metabolic indices.
et al., 2006a and Rokamp et al., 2013) of variable age (Rokamp
et al., 2013), but a smaller population size (n = 40 compared
to n = 72 (Snyder et al., 2006a) and n = 140 (Rokamp
et al., 2013), respectively) and while Snyder et al. (2006a)
used the open-circuit acetylene uptake method, we used the
Model-flow method (Bogert and van Lieshout, 2005). Model-
flow seems to underestimate the increase in CO during heat
stress (Shibasaki et al., 2011), but has been successfully validated
against a thermodilution estimate in healthy subject during
orthostatic stress (Harms et al., 1999) and in patients with
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septic shock (Jellema et al., 1999), during liver transplantation
and cardiac surgery (Jansen et al., 2001; Nissen et al.,
2009).
The systemic increase in glucose following adrenaline
stimulation is expected from increased endogen glucose
production and a sustained inhibitory effect on glucose
clearance (Rizza et al., 1980a). The β-adrenoceptor subtype
that mediates catecholamine-induced systemic hyperglycemia
is proposed to be of the β2-subtype (Kuo et al., 1977), and
the adrenaline derived decrease in glucose clearance is
predominantly by a β-adrenergic mechanism (Rizza et al.,
1980b). This complies with the finding that the elevation
in arterial glucose is associated with the ADRB2 Gly16
polymorphism and may be explained by an elevated β2-
adrenergic response in the Gly16 homozygotes. The difference
in metabolic response according to genotype may arise
from a difference in number of receptors, i.e., Snyder et al.
(2006b) found an increased density of β2-receptors on
lymphocytes from Gly16 homozygotes compared with Arg16
homozygotes.
In patients with longstanding type 1 diabetes, blunting of
the glucagon response comes along with the disappearing
endogenous insulin production (Cryer, 2008), rendering the
patients increasingly dependent upon epinephrine as protection
against hypoglycemia. As a result of recurrent hypoglycemia
and/or long duration of diabetes, also the epinephrine response
to hypoglycemia becomes blunted, leading to an increased risk of
severe hypoglycemia (Høi-Hansen et al., 2010). In addition to the
failing catecholamine response to hypoglycemia with impaired
hypoglycemia awareness, a reduced β2-adrenergic sensitivity
has been reported in some (Korytkowski et al., 1998; Fritsche
et al., 2001), but not all studies (De Galan et al., 2006). In
accordance, treatment with non-specific β-blockers with effect on
the β2-receptor is associated with reduced endogenous glucose
production to adrenaline infusion (Shamoon and Sherwin, 1984),
impaired recovery from hypoglycemia (Lager, 1983; Popp et al.,
1984), and probably an increased risk of severe hypoglycemia in
type 1 diabetes. The difference between genotypes in systemic
adrenergic glucose response is novel and we speculate that it
may be of clinical importance in patients with type 1 diabetes.
The glucose response in this study was under conditions
with baseline normoglycemia and cannot be compared to the
conditions during hypoglycemia. Further studies are needed
to uncover the genetic impact on glucose mobilization during
hypoglycemia.
LIMITATIONS
The limitations of the study include not monitoring plasma
insulin. There were no differences in arterial glucose level at
baseline, but the Gly16 allele has been associated with increased
insulin levels (Ikarashi et al., 2004) and plasma insulin increase
initially in response to adrenaline (Sherwin and Saccà, 1984).
Plasma catecholamine levels are not monitored in this
study, but earlier there have been found no difference between
genotypes in catecholamine levels during rest or exercise (Snyder
et al., 2006a).
The steady state of plasma glucose is not reached during 60
min of adrenaline infusion, and differences in plasma glucose
is therefore lower than would be expected if time of adrenaline
infusion had been extended.
SUMMARY AND CONCLUSION
An association was found between the G16G genotype and
adrenaline induced increase in arterial glucose with no difference
at baseline. We found no other relevant differences between
genotypes in any other measured cardiovascular or cerebral
variable at baseline or during adrenaline infusion. In conclusion,
the metabolic response of glucose during adrenergic stimulation
with adrenaline is associated to the G16R polymorphism of
ADRB2, although without effect on cerebral metabolism.
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